Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XMU
|
|||
| Former ID |
DAP000841
|
|||
| Drug Name |
Testosterone
|
|||
| Synonyms |
AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Approved | [1], [2] | |
| Hormone deficiency [ICD-11: 5A61.1] | Phase 2 | [3] | ||
| Male hormonal deficiency [ICD-11: 5A81] | Investigative | [4], [5] | ||
| Company |
Ardana Bioscience
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H28O2
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
|
|||
| InChI |
1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
|
|||
| InChIKey |
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
|
|||
| CAS Number |
CAS 58-22-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3817, 584560, 625875, 819215, 822362, 822363, 822524, 823294, 841439, 3136424, 7847143, 7890744, 8144176, 8153742, 10318947, 12012605, 14849069, 14873306, 17389513, 22400338, 24702263, 24870573, 24899970, 24900279, 26717586, 26717589, 26717592, 26717594, 29225027, 46501387, 46505691, 48421877, 48425662, 49703436, 50049744, 50085980, 53789940, 56311126, 56311276, 56312112, 56312748, 56313357, 56313477, 56313560, 56313804, 56314183, 56314208, 56462804, 57288851, 57323115
|
|||
| ChEBI ID |
CHEBI:17347
|
|||
| ADReCS Drug ID | BADD_D02170 | |||
| SuperDrug ATC ID |
G03BA03
|
|||
| SuperDrug CAS ID |
cas=000057852
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2858). | |||
| REF 2 | Emerging drugs for hypogonadism. Expert Opin Emerg Drugs. 2006 Nov;11(4):685-707. | |||
| REF 3 | ARDANA ANNOUNCES PHASE I RESULTS FOR TESTOSTERONE CREAM. FDAnews report. | |||
| REF 4 | Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24. | |||
| REF 5 | Complexities of androgen action. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S87-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.